Urinary tract infection in patients with neuropathic bladder

The session was prompted by the high volume of UTI‑related questions during a previous non‑neurogenic lower urinary tract symptoms (LUTS) webinar, highlighting how challenging this topic is in everyday practice.

Why UTIs in Neuropathic Bladder Are Different

Across the talks, a consistent message emerged:

• Higher risk, more complexity

  • Incomplete bladder emptying, catheter use (intermittent self catheterisation (ISC), indwelling, suprapubic) and reconstructive urinary diversions all increase UTI risk.

  • Patients often have multiple comorbidities (e.g. diabetes, obesity) and are frequently on immunomodulating or antispasticity/antiepileptic medication, further complicating risk and presentation.

• Different microbiology and resistance profile
  • Compared with community UTIs (predominantly E. coli), neurogenic bladder patients show:

    • More diverse flora (Klebsiella, Proteus, Pseudomonas, Enterococci)

    • More polymicrobial infections and biofilm‑associated infection

    • Higher rates of multidrug resistance, including Extended Spectrum Beta-lactamase (ESBLs) and emerging carbapenemase‑producing organisms

  • Empirical choices like trimethoprim, co‑amoxiclav and ciprofloxacin are increasingly unreliable, reinforcing the need for culture‑guided therapy.

Key Clinical Messages & Outcomes

1. Asymptomatic Bacteriuria: Don’t Over‑Treat

• Asymptomatic bacteriuria (ASB) is extremely common in:

  • Long‑term catheter users

  • Patients with spinal cord injury and complex neurogenic bladders

• Core recommendation:
  • Treat only when there are symptoms or systemic signs (e.g. fever, new pain, autonomic dysreflexia, clear functional change), or:

    • Prior to urological procedures

    • In pregnancy

• Repeated treatment of ASB:

  • Drives resistance

  • Increases risk of fungal infection and C. difficile

  • Often does not eradicate colonisation

• Panel stressed the importance of patient education so individuals understand that “positive cultures” without symptoms do not always mean ‘infection needing antibiotics’.

2. Getting the Sample Right

Good microbiology starts with good sampling:

• Non‑catheterised patients: aim for a true midstream urine (MSU) and explain the technique clearly.

• Catheterised patients:

  • Sample from the sampling port, not from the bag.

  • Consider changing a long‑term catheter before sampling in complex/recurrent cases to understand what’s really happening in the bladder.

  • Clearly label the sample type (MSU vs catheter, long‑term vs fresh) – this changes how the lab interprets results.

Poor sampling and labelling lead to misleading cultures, confusion about “mixed growth”, and unnecessary antibiotics.

3. Managing Multidrug‑Resistant UTIs

For MDR infections in neurogenic bladders:

• Base treatment on culture and sensitivities whenever possible.

• Avoid repeated, blind empirical courses – they select for further resistance.

• Options discussed include:

  • Fosfomycin (especially for certain MDR Gram‑negatives)

  • Aminoglycosides (gentamicin, amikacin; systemically or intravesically in specialist settings)

  • Carbapenems (e.g. meropenem) reserved for severe/systemic infection

  • Newer, high‑cost agents (e.g. newer cephalosporin/β‑lactamase inhibitor combinations) guided by microbiology/ID teams

• IV–to–oral switch should be pursued where safe; MDR infection is not in itself a reason for prolonged IV or prolonged duration.

The panel strongly encouraged early microbiology/infectious diseases input in:

• Recurrent UTIs (>3/year)

• MDR organisms

• Treatment failures despite “susceptible” reports

• Patients needing long‑term IV or suppressive strategies

4. Bladder Management & Mechanical Risk Factors

Mr Boxall focused on how bladder mechanics and drainage methods drive UTI risk:

• ISC remains the gold standard when feasible:

  • Lower biofilm burden than indwelling catheters

  • But still carries risks of trauma, bacterial introduction, and over‑ or under‑catheterisation

  • Technique, catheter design (e.g. micro‑hole technology) and frequency all matter.

• Indwelling catheters (urethral or suprapubic):
  • There is no strong evidence that one route has clearly fewer infections, but:

    • Suprapubic catheters are often easier to manage and less disruptive to the urethra and sexual function.

  • Flip‑flow / clamp‑and‑release strategies can improve:

    • Flushing of biofilm and debris

    • Bladder viscoelasticity and low‑pressure storage

    • Potentially reduce infection and upper tract risk

• High‑pressure bladders, reflux, and poor drainage:

  • Increase risk of upper tract involvement and infection

  • May benefit from interventions such as Botox, optimised catheter strategies, and tailored reconstructive approaches.

5. Investigation of Recurrent UTIs in Neuropathic Patients

For neuropathic patients with recurrent UTIs, the faculty emphasised structured investigation:

• Baseline renal tract ultrasound – look for:

  • Scarring

  • Hydronephrosis/obstruction

  • Stones

• Cystoscopy:

  • Detect small stones, foreign bodies, malignancy

  • Allows bladder washout

• Urodynamics:

  • Assess pressures, compliance, and reflux risk

  • Guide changes in bladder management to protect kidney function and reduce infection risk

6. Preventive & Non‑Antibiotic Strategies

Miss Nadeem outlined a stepwise preventive approach, before or alongside antibiotics:

• Cranberry products

  • PACs may inhibit E. coli adherence; evidence mainly in non‑neurogenic women and is modest.

  • Low risk profile; can be offered as a supplement with appropriate counselling.

• D‑mannose

  • Monosaccharide that blocks bacterial adherence (mainly E. coli).

  • Shown benefit vs. placebo and similar performance to some prophylactic antibiotics in non‑neurogenic women.

  • Generally safe, including in diabetes (though poorly controlled diabetics may warrant individual discussion with endocrinology).

  • Emerging evidence suggests evening dosing might be optimal.

• Methenamine hippurate

  • Urinary antiseptic that generates formaldehyde in acidic urine, most active against E. coli, Klebsiella, Proteus.

  • Supported by the ALTAR trial in women with recurrent uncomplicated UTIs as non‑inferior to low‑dose antibiotic prophylaxis.

  • Neurogenic bladders may respond differently, but it can:

    • Help reduce infection rates

    • Reduce crystallisation and stone formation

  • In catheterised neuropathic patients, higher frequency dosing (up to three times daily) may be considered, often with vitamin C to acidify urine.

• Antibiotic prophylaxis
  • Reserved for carefully selected patients:

    • Recurrent, clinically significant UTIs despite optimal bladder management and first‑line preventive measures.

  • Requires clear counselling about:

    • Resistance, C. difficile, adverse effects

  • Best managed with time‑limited trials and microbiology/ID input where possible.

• Topical vaginal oestrogen (peri‑ and post‑menopausal women)

  • Strong rationale for use in women with recurrent UTIs, including neuropathic patients.

  • Modern evidence and guidelines indicate low‑dose vaginal oestrogen is safe, including in women with a history of breast or endometrial cancer, when appropriately assessed and documented (liaising with oncology if active disease).

  • Must emphasise:

    • Adequate dosing and correct application (vulval and intravaginal)

    • Ongoing compliance

  • Particularly valuable when catheterisation and local irritation coexist.

• Vaccines (OM‑89, MV140/Uromune)

  • Sublingual bacterial vaccines show promise in non‑neurogenic, non‑catheterised patients.

  • Limited data in neuropathic/catheterised cohorts; use remains selective and often outside standard NHS pathways.

  • May be considered earlier in suitable patients with simple, antibiotic‑sensitive UTIs to reduce antibiotic exposure.

• Intravesical therapies
  • Antibiotic instillations (e.g. gentamicin, amikacin):

    • Particularly suitable for ISC‑capable neuropathic patients.

    • Allow high local concentrations with minimal systemic exposure.

    • In one shared protocol, patients self‑instil according to a structured tapering regimen with nurse support.

    • Reported outcomes include:

      • Marked reduction in MDR isolates

      • Fewer hospital admissions

      • Greater patient autonomy and disease understanding

  • GAG‑layer replacement therapy:

    • Aimed at restoring the damaged glycosaminoglycan layer to reduce bacterial adherence and chronic symptoms.

    • Best suited to:

      • Patients with UTI‑like symptoms but negative cultures

      • Those with very limited systemic antibiotic options

    • Requires infection‑free windows; not used during active infection.

• Emerging approaches (bacteriophage, microbubbles, microbiota transplantation)

  • Currently confined to research settings; not ready for routine practice.

7. Multidisciplinary Working

A clear outcome from the webinar was the value of formal UTI MDTs for complex neuropathic patients, typically involving:

• Neuro‑urologists

• Microbiologists/infectious diseases specialists

• Specialist nurses

• Pharmacists

• Neurologists and rehabilitation teams as needed

Such MDTs support:

• Personalised, realistic treatment plans

• Antimicrobial and diagnostic stewardship

• Decisions on intravesical or vaccine therapies

• Planning around surgery or major interventions

Key Points

• UTIs in neuropathic/neurogenic bladders are fundamentally different from typical community UTIs – the organisms, resistance patterns, presentations, and risks are more complex.

• Not all positive urine cultures need antibiotics.Avoiding treatment of asymptomatic bacteriuria is central to good care and antimicrobial stewardship.

• Bladder management is as important as microbiology.The way the bladder is drained – and at what pressures – directly affects infection risk and renal safety.

• A stepwise, prevention‑first strategy using non‑antibiotic measures, bladder optimisation, and careful investigation can significantly reduce infection burden.

• Multidisciplinary input (neuro‑urology, microbiology/ID, specialist nursing) is crucial for recurrent, resistant, or otherwise complex UTIs.

• The Uro Neurology Academy will continue to support clinicians through webinars, on‑demand content, and the upcoming Masterclass covering bladder, bowel and sexual dysfunction, with a strong focus on practical, case‑based learning.